Formycon, a Germany-based biosimilar manufacturer, shared that its revenues for 2023 were 83% higher than in 2022, reaching a total of €77.7 million, according to its annual earnings report.
Related Keywords
Germany , Fresenius Kabi , Stefan Glombitza , Enno Spillner , Formycon Group , European Medicines Agency , European Medicines , Formycon , Bustekinumab , Earnings Report ,
comparemela.com © 2020. All Rights Reserved.